Discovering significant breakthroughs in fibrosis.
Blade Clinical Trials
Today, we are advancing a robust pipeline of potential first-in-class investigational small-molecule therapies to combat diseases of lung, liver and heart fibrosis, as well as neuro-degenerative conditions. This includes multiple direct inhibitors of autotaxin / LPA and dimeric calpains that offer distinct but complementary anti-fibrotic mechanisms.
Find Clinical Trials Near Me
| Program | Indication | Study Phase | Status | Trial number |
|---|---|---|---|---|
| BLD-0409 | Healthy Volunteer Safety Testing | Phase 1 | Complete | NCT04146805 |
| BLD-0409-102 | Relative Bioavailability | Phase 1b | In Process | NCT04814472 |
| BLD-0409-103 | Drug-Drug Interaction | Phase 1b | In Process | NCT04814498 |
| BLD-0409-203 | Idiopathic Pulmonary Fibrosis | Phase 2 | Planned | |
| BLD-0409-210 | Interstitial Lung Disease | Phase 2 | Planned |
Chronic Liver Disease
Blade’s autotaxin inhibitor, BLD-0409, is being studied in a Phase 1 double-blind, randomized, placebo-controlled, multiple cohort, single and multiple ascending dose trial to assess safety, tolerability and pharmacokinetics in healthy participants (Clinicaltrials.gov NCT04146805).